This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Concert Pharmaceuticals 過去の業績
過去 基準チェック /06
主要情報
-45.4%
収益成長率
-40.8%
EPS成長率
| Biotechs 業界の成長 | 17.0% |
| 収益成長率 | 47.4% |
| 株主資本利益率 | -94.8% |
| ネット・マージン | -395.4% |
| 前回の決算情報 | 30 Sep 2022 |
最近の業績更新
Recent updates
Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?
Jan 22
CinCor Pharma hits 52-week high on data for antihypertensive agent
Aug 08Concert Pharmaceuticals: A Balanced Risk/Reward
Jun 15We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
Jun 04Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug
Jun 03Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans
Jan 11Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Aug 27We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
May 25Concert Pharma EPS beats by $0.02
May 04Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years
Feb 27Concert Pharma fails in mid-stage study for CTP-692 Schizophrenia
Feb 01Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Jan 23How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?
Dec 19
A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns
Nov 23Concert Pharma EPS beats by $0.15
Nov 05Concert Pharma launches late-stage study of CTP-543 in hair loss disorder
Nov 03収支内訳
収支内訳
Concert Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Sep 22 | 32 | -127 | 22 | 0 |
| 30 Jun 22 | 33 | -125 | 22 | 0 |
| 31 Mar 22 | 33 | -95 | 23 | 0 |
| 31 Dec 21 | 33 | -80 | 23 | 0 |
| 30 Sep 21 | 1 | -66 | 22 | 0 |
| 30 Jun 21 | 2 | -59 | 21 | 0 |
| 31 Mar 21 | 8 | -77 | 20 | 0 |
| 31 Dec 20 | 8 | -75 | 19 | 0 |
| 30 Sep 20 | 8 | -73 | 19 | 0 |
| 30 Jun 20 | 6 | -71 | 19 | 0 |
| 31 Mar 20 | 0 | -77 | 19 | 0 |
| 31 Dec 19 | 1 | -78 | 20 | 0 |
| 30 Sep 19 | 1 | -79 | 21 | 0 |
| 30 Jun 19 | 1 | -79 | 22 | 0 |
| 31 Mar 19 | 1 | -73 | 23 | 0 |
| 31 Dec 18 | 11 | -56 | 23 | 0 |
| 30 Sep 18 | 11 | -41 | 23 | 0 |
| 30 Jun 18 | 11 | 104 | 21 | 0 |
| 31 Mar 18 | 11 | 104 | 21 | 0 |
| 31 Dec 17 | 0 | 95 | 21 | 0 |
| 30 Sep 17 | 0 | 89 | 19 | 0 |
| 30 Jun 17 | 0 | -50 | 18 | 0 |
| 31 Mar 17 | 0 | -50 | 16 | 0 |
| 31 Dec 16 | 0 | -51 | 14 | 0 |
| 30 Sep 16 | 10 | -38 | 14 | 0 |
| 30 Jun 16 | 12 | -35 | 14 | 0 |
| 31 Mar 16 | 15 | 19 | 13 | 0 |
質の高い収益: CNCE is currently unprofitable.
利益率の向上: CNCE is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: CNCE is unprofitable, and losses have increased over the past 5 years at a rate of 45.4% per year.
成長の加速: Unable to compare CNCE's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: CNCE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.2%).
株主資本利益率
高いROE: CNCE has a negative Return on Equity (-94.78%), as it is currently unprofitable.